Evidence map›Paper›PMID 23722008›Full record

ReviewClinical oncology (Royal College of Radiologists (Great Britain))2013

Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer.

B Turkbey, E Mena, O Aras, B Garvey, K Grant, P L Choyke

Abstract readReview
In one paragraph

Review in Clinical oncology (Royal College of Radiologists (Great Britain)), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.European journal of nuclear medicine and molecular imaging · 2016
    Article
  5. DCE MRI of prostate cancer.Abdominal radiology (New York) · 2016
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.American journal of nuclear medicine and molecular imaging · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

B TurkbeyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1088, USA. turkbeyi@mail.nih.gov
E Mena
O Aras
B Garvey
K Grant
P L Choyke

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Intramural NIH HHS ZIA BC010655
6 · The paper itself

Abstract

Prostate cancer is currently the most common solid organ cancer type among men in the Western world. Currently, all decision-making algorithms and nomograms rely on demographics, clinicopathological data and symptoms. Such an approach can easily miss significant cancers while detecting many insignificant cancers. In this review, novel functional and molecular imaging techniques used in the diagnosis and staging of localised prostate cancer and their effect on treatment decisions are discussed.

Indexed as

HumansMaleMolecular ImagingNeoplasm StagingProstatic NeoplasmsRadiographyLocalizationMRIPET/CTprostate cancerstaging

Identifiers

PMID23722008
PMCPMC6330112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.